InnoCare Announces First Patient Dosed in Clinical Trial of Novel CDH17 targeted ADC ICP-B208 in China

Trial StartICP-B208Positive

AI Analysis

Summary

InnoCare announced the first patient dosed in a clinical trial of ICP-B208, a novel CDH17-targeted antibody-drug conjugate (ADC) developed from its in-house platform, marking the second ADC from the company to enter clinical development with no approved competing agents globally.

Clinical Trial Data

Outcome Details

First patient dosed in clinical trial

Importance:5/10

Sentiment:

0.50

ADCCDH17Chinaclinical_trialoncologynovel_target

Related Companies

$CHHE $TRAX

Read the original article

Published by GlobeNewswire Clinical Studies on July 6, 2026 1:00 AM

Read Original